Charles River Laboratories Intl. Inc vs Sea Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Sea Limited trades at $95.25 (market cap $56.89B). The key difference: Sea Limited is far larger — about 4× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Sea Limited for 102 Days on average.
| CRL | SE | |
|---|---|---|
Market Cap | $14.23B | $56.89B |
Volume | 1,176,885 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $182.60 |
52-Week Low | $149.93 | $78.16 |
Typical Hold Time | 33 Days | 102 Days |
Enterprise Value | $17.06B | $51.92B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
Sea Limited (SE) trades at $92.89, down 1.87% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. Fundamentally, the company demonstrates strong revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income improving to $1.58B. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $153.67 consensus price target, representing 65% upside potential. Recent news highlights insider selling activity but also bullish analyst commentary on Shopee's growth prospects.
The investment case hinges on Sea's ability to maintain e-commerce momentum while improving profitability. Key risks include competitive pressures in Southeast Asian markets and execution challenges in scaling operations. With shares trading well below analyst targets and showing improved cash flow generation, the current price level presents a potential entry point for growth-oriented investors willing to tolerate near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →